AbSci: Buy Rating Reaffirmed as ABS-201 Hair-Loss Program Advances; $11 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.Needham analyst Gil Blum reaffirmed a Buy rating on AbSci (ABSI) with an $11 price target, citing the advancement of its lead program ABS-201 for hair loss and a strong cash position of $201M. The analyst views the upcoming 2026 clinical data as a key catalyst. TD Cowen also maintained a Buy rating.
Needham analyst Gil Blum has maintained their bullish stance on ABSI stock, giving a Buy rating yesterday.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Gil Blum has given his Buy rating due to a combination of factors related to AbSci’s lead program and financial position. He views ABS-201 for pattern hair loss as the core driver of shareholder value, with a key 13-week interim data read from randomized multiple-ascending-dose cohorts expected in the second half of 2026, providing a meaningful clinical catalyst.
Blum highlights the innovative prolactin-blocking mechanism, noting that even early, directional signs of hair regrowth could be materially positive, especially since ABS-201 could be used alongside existing treatments like finasteride and oral minoxidil. Coupled with AbSci’s solid cash balance of $201M after its recent $100M raise, which should fund operations into the second half of 2028, he sees sufficient runway to reach value-inflecting milestones and thus reiterates his $11 price target and Buy rating.
According to TipRanks, Blum is a 5-star analyst with an average return of 16.3% and a 46.98% success rate. Blum covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Fate Therapeutics, and Cartesian Therapeutics.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.